Search results for "Chromosomal Deletion"

showing 7 items of 7 documents

Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in DYRK1A.

2015

The dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) gene, located on chromosome 21q22.13 within the Down syndrome critical region, has been implicated in syndromic intellectual disability associated with Down syndrome and autism. DYRK1A has a critical role in brain growth and development primarily by regulating cell proliferation, neurogenesis, neuronal plasticity and survival. Several patients have been reported with chromosome 21 aberrations such as partial monosomy, involving multiple genes including DYRK1A. In addition, seven other individuals have been described with chromosomal rearrangements, intragenic deletions or truncating mutations that disrupt specificall…

AdultMaleMicrocephalyMonosomyDown syndromeAdolescentChromosomes Human Pair 21BiologyProtein Serine-Threonine KinasesArticleIntellectual DisabilityIntellectual disabilityGeneticsmedicineHumansAutistic DisorderChildGenetics (clinical)Chromosomal DeletionGeneticsProtein-Tyrosine Kinasesmedicine.diseasePhenotypeChild PreschoolSpeech delayMutationMicrocephalyAutismFemalemedicine.symptomChromosome DeletionDown SyndromeChromosome 21European journal of human genetics : EJHG
researchProduct

Ras-pathway has a dual role in yeast galactose metabolism

2007

AbstractIn the yeast Saccharomyces cerevisiae the genes involved in galactose metabolism (GAL1,7,10) are transcriptionally activated more than a 1000-fold in the presence of galactose as the sole carbon source in the culture media. In the present work, we monitored the activity of the GAL10 gene promoter in different Ras-cAMP genetic backgrounds. We demonstrate that overexpression of C-terminus of the nucleotide exchange factor Cdc25p stimulates GAL10 transcription in yeast strains carrying the contemporary deletion of both RAS genes. Moreover, the deletion of the chromosomal CDC25 gene provokes impaired growth on galactose based media in yeast strain lacking both RAS genes and adenylate cy…

Galactose metabolismSaccharomyces cerevisiae ProteinsSaccharomyces cerevisiaeBiophysicsGene ExpressionSaccharomyces cerevisiaeRas glucose and galactose metabolism cancerGTP-binding proteinSignal transductionBiochemistryLeloir pathwaychemistry.chemical_compoundRas-GRF1Protein kinase AStructural BiologyGenes ReporterGene Expression Regulation FungalGeneticsRNA MessengerProtein kinase APromoter Regions GeneticMolecular BiologyChromosomal DeletionAllelesbiologyras-GRF1GalactosePromoterCell Biologybiology.organism_classificationLeloir pathwayExchange factorPhenotypechemistryBiochemistryGalactoseras ProteinsSignal transductionGene DeletionAdenylyl CyclasesPlasmidsFEBS Letters
researchProduct

Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes

2013

Neuroblastoma is an embryonic tumor arising from immature sympathetic nervous system cells. Recurrent genomic alterations include MYCN and ALK amplification as well as recurrent patterns of gains and losses of whole or large partial chromosome segments. A recent whole genome sequencing effort yielded no frequently recurring mutations in genes other than those affecting ALK. However, the study further stresses the importance of DNA copy number alterations in this disease, in particular for genes implicated in neuritogenesis. Here we provide additional evidence for the importance of focal DNA copy number gains and losses, which are predominantly observed in MYCN amplified tumors. A focal 5 kb…

TRANSCRIPTIONAL TARGETNeuroblastoma/geneticsPsychologie appliquéeMedizinlcsh:MedicineChromosomal DisordersNeuroblastoma0302 clinical medicineRGS Proteins/geneticsGene duplicationMolecular Cell BiologyBasic Cancer ResearchTUMOR-SUPPRESSORALK KINASElcsh:ScienceNeurological TumorsGeneticsRegulation of gene expressionOncogene Proteins0303 health sciencesN-Myc Proto-Oncogene ProteinACTIVATING MUTATIONSMultidisciplinaryCancer Risk FactorsHomozygoteChromosomal Deletions and DuplicationsNuclear ProteinsGenomicsSciences bio-médicales et agricolesSignaling in Selected DisciplinesCANCEROncogene Proteins/geneticsGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisMedicineRNA Long NoncodingBiologieResearch ArticleSignal TransductionEXPRESSIONDNA Copy Number VariationsGenetic Causes of CancerDown-RegulationGenomicsBiologyMolecular Genetics03 medical and health sciencesGenome Analysis ToolsNeuroblastomaCell Line TumormicroRNAmedicineGeneticsCancer GeneticsHumansGene RegulationGeneneoplasmsBiology030304 developmental biologyOncogenic SignalingN-MYCTHERAPEUTIC TARGETRECEPTORMICRORNAlcsh:RBiology and Life SciencesChromosomeCancers and NeoplasmsHuman Geneticsmedicine.diseaseNuclear Proteins/geneticsMicroRNAs/geneticsMicroRNAsPediatric Oncologylcsh:QGenome Expression AnalysisN-MycRGS ProteinsPLoS ONE
researchProduct

Myelodysplastic Syndromes with 20q Deletion: Incidence, Prognostic Value and Impact on Response to Azacitidine of ASXL1 Chromosomal Deletion and Gene…

2020

Introduction : The 20q deletion [del(20q)] is a recurrent chromosomal aberration in myelodysplastic syndromes (MDS) and, as a single abnormality, is associated according to the Revised International Prognostic Scoring System (IPSS-R) with a favorable outcome. However, the breakpoint of del(20q) is very heterogeneous and may cause deletion of the ASXL1 gene (20q11.21). This gene is an important epigenetic regulator of hematopoiesis and its mutations have been associated in MDS with a shorter overall survival (OS) and a lower response to azacitidine (AZA). Aim: To assess the incidence, prognostic value and impact on response to AZA of ASXL1 chromosomal alterations and genetic mutations in MDS…

OncologySanger sequencingmedicine.medical_specialtybusiness.industryMyelodysplastic syndromesImmunologyAzacitidineBreakpointCell BiologyHematologymedicine.diseaseBiochemistryIDH2symbols.namesakeGermline mutationInternational Prognostic Scoring SystemInternal medicinesymbolsMedicinebusinessChromosomal Deletionmedicine.drugBlood
researchProduct

Pyomelanin-producingPseudomonas aeruginosaselected during chronic infections have a large chromosomal deletion which confers resistance to pyocins

2016

When bacterial lineages make the transition from free-living to permanent association with hosts, they can undergo massive gene losses, for which the selective forces within host tissues are unknown. We identified here melanogenic clinical isolates of Pseudomonas aeruginosa with large chromosomal deletions (66 to 270 kbp) and characterized them to investigate how they were selected. When compared with their wild-type parents, melanogenic mutants (i) exhibited a lower fitness in growth conditions found in human tissues, such as hyperosmolarity and presence of aminoglycoside antibiotics, (ii) narrowed their metabolic spectrum with a growth disadvantage with particular carbon sources, includin…

0301 basic medicineGeneticseducation.field_of_studyPseudomonas aeruginosamedicine.drug_class030106 microbiologyAntibioticsPopulationMutantDrug resistanceBiologymedicine.disease_causeMicrobiology3. Good healthMicrobiologyBacterial genetics03 medical and health sciences030104 developmental biologymedicineeducationGeneEcology Evolution Behavior and SystematicsChromosomal DeletionEnvironmental Microbiology
researchProduct

Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and gene…

2021

In myelodysplastic syndromes (MDS), the 20q deletion [del(20q)] may cause deletion of the ASXL1 gene. We studied 153 patients with MDS and del(20q) to assess the incidence, prognostic value and impact on response to azacitidine (AZA) of ASXL1 chromosomal alterations and genetic mutations. Additionally, in vitro assay of the response to AZA in HAP1 (HAP1(WT)) and HAP1 ASXL1 knockout (HAP1(KN)) cells was performed. ASXL1 chromosomal alterations were detected in 44 patients (28 center dot 5%): 34 patients (22%) with a gene deletion (ASXL1(DEL)) and 10 patients (6 center dot 5%) with additional gene copies. ASXL1(DEL) was associated with a lower platelet count. The most frequently mutated genes…

MaleOncologyAntimetabolites Antineoplasticazacitidinemedicine.medical_specialtyAzacitidineASXL1Gene mutationInternal medicinemedicineHumansGeneChromosomal DeletionAged20q deletiongene mutationsAged 80 and overbusiness.industryIncidenceMyelodysplastic syndromesIncidence (epidemiology)Hazard ratioHematologyMiddle AgedPrognosismedicine.diseasemyelodysplastic syndromesConfidence intervalRepressor ProteinsMyelodysplastic SyndromesMutationAzacitidineFemaleChromosome Deletionbusinessmedicine.drugBritish Journal of Haematology
researchProduct

Cri du chat syndrome: A critical review

2009

A new syndrome was identified in 1963, when Lejeune et al. reported a genetic disease resulting from a partial or total deletion on the short arm of chromosome 5 (5p-) and named it the cri du chat syndrome (CdCS). This term makes reference to the main clinical feature of the syndrome, a high-pitched monochromatic cat-like crying, that usually disappears in the first years of life. CdCS is one of the most common chromosomal deletion syndromes in humans, with an incidence of 1:15.000-1:50.000 live-births. Our purpose was to review different aspects of this syndrome (concept, epidemiology, aetiology, clinical features,diagnostic methods and prognosis) emphasizing both: the breakthrough in this…

Cri-du-Chat Syndromemedicine.medical_specialtyPediatricsPathologybusiness.industryIncidence (epidemiology)Cri du chat syndromeCri du Chat SyndromeTooth eruptionDiseaseEnamel hypoplasia:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseOrofacial manifestationOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASEpidemiologyEtiologyHumansMedicineSurgerybusinessGeneral DentistryChromosomal DeletionChromosome disorders
researchProduct